The negative P/E renders traditional earnings-based valuation meaningless; the market is instead pricing a 'call option' on the company's future technology adoption. The P/B ratio, while nominally low, is inflated by a book value dominated by accumulated losses rather than tangible assets, suggesting the premium is driven by the scarcity value of a licensed SMR design rather than current fundamentals.

Unlike a regulated utility with an authorized return, NuScale operates with no approved revenue requirement. The extreme volatility in ROE, swinging from -2.9% to -58.5% and back to -3.0%, indicates earnings are driven by episodic development costs and project write-downs, not a stable regulated asset base. This disconnect from utility norms is the primary analytical challenge.

The margin profile, as seen in financial statements, is that of a high-tech R&D firm, not a utility. Costs are capitalized or expensed with no corresponding revenue stream, meaning every dollar of operational spending directly erodes capital. The lack of any positive margin trend since the project cancellation signals a total absence of near-term cost recovery mechanisms.

The zero-debt balance sheet is a facade of strength; the company's capital structure is entirely equity-funded, with total debt of just $6.7M against $2.1B in equity. This creates a misleadingly low leverage ratio while the true financial risk is extreme equity dilution, as the company must continuously raise capital to fund its negative cash flows.

For a utility, the absence of a dividend would be a critical red flag. For NuScale, it simply reflects its stage of development. The relevant metric is not payout coverage but the internal funding gap—the negative free cash flow must be financed entirely through external equity, making the dividend framework wholly inapplicable.